LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Intellia Therapeutics Inc

Fermé

SecteurSoins de santé

8.07 6.75

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.56

Max

8.39

Chiffres clés

By Trading Economics

Revenu

15M

-114M

Ventes

3.8M

17M

BPA

-1.1

Marge bénéficiaire

-687.611

Employés

403

EBITDA

16M

-118M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+301.58% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-174M

742M

Ouverture précédente

1.32

Clôture précédente

8.07

Sentiment de l'Actualité

By Acuity

4%

96%

1 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Intellia Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

22 avr. 2025, 09:30 UTC

Actualités

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

12 sept. 2024, 17:01 UTC

Actualités

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 sept. 2024, 11:00 UTC

Actualités

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparaison

Variation de prix

Intellia Therapeutics Inc prévision

Objectif de Prix

By TipRanks

301.58% hausse

Prévisions sur 12 Mois

Moyen 30.44 USD  301.58%

Haut 65 USD

Bas 8 USD

Basé sur 21 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

21 ratings

16

Achat

4

Maintien

1

Vente

Score Technique

By Trading Central

7.24 / 8.43Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

1 / 380Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.